Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Stock Quote Today & Recent News Marker Therapeutics Inc MRKR

Healthcare Biotechnology
Marker Therapeutics, Inc. is a clinical-stage immuno-oncology company. The Company specializes in the development and commercialization of novel T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications. It has developed its lead product candidates from its multiTAA-specific T cell technology, which is based on the manufacture of non-engineered... see more
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >

Current News (NDAQ:MRKR)

Marker Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Updates

GlobeNewswire 11 days ago

Korro Announces Addition of Industry Veteran Katharine Knobil to and Resignation of David Lucchino From Its Board of Directors

GlobeNewswire August 28, 2024

Marker Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Updates

GlobeNewswire August 14, 2024

Marker Therapeutics Awarded $2 Million Grant from NIH in Support of Phase 1 Study Investigating MT-601 in CAR-Relapsed Patients with Non-Hodgkin's Lymphoma

GlobeNewswire August 12, 2024

Marker Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Updates

GlobeNewswire May 15, 2024

Principal Investigator from City of Hope National Medical Center Invited to Present Clinical Data from Marker Therapeutics APOLLO Study at 11th Global Summit on Hematologic Malignancies 

GlobeNewswire April 8, 2024

Marker Therapeutics Reports Year-End 2023 Corporate and Financial Results

GlobeNewswire March 25, 2024

Marker Therapeutics to Present at the H.C. Wainwright 2nd Annual Cell Therapy Virtual Conference

GlobeNewswire March 22, 2024

Marker Therapeutics Receives Approval from United States Adopted Name (USAN) Council and International Nonproprietary Names (INN) Expert Committee for "Neldaleucel" as Nonproprietary Name for MT-601

GlobeNewswire January 22, 2024
View More News ››

Opinion & Analysis (NDAQ:MRKR)

Interim Data Indicate Multiantigen Cell Therapy in Solid Tumors 'Just Might Work'

Streetwise Reports July 24, 2019
View More Opinion ››

Bullboard Posts (NDAQ:MRKR)

Marker Therapeutics, Inc. (MRKR): Navigating the Complexitie

http://beyondspx.com/2024/07/31/marker-therapeutics-inc-mrkr-navigating-the-complexities-of-immuno-oncology-2/
MikeTester - August 2, 2024

Principal Investigator from City of Hope National Medical Ce

Breaking News: $MRKR Principal Investigator from City of Hope National Medical Center Invited to Present Clinical Data from Marker...
whytestocks - April 8, 2024

I've heard of this company

The Mayo Clinic has gotten DOD grant and they are working on some vacines. 
Carver78 - March 21, 2017

heavy volume and price up

Well, today we had 4.7 million shares trade(14.4% of total outstanding shares), and a price increase of 31.18%.  It appears that...
thlove - May 11, 2015

Another Thursday trade with Profit on Friday

This was another trade that was mentioned on my blog about being patient and having the discipline to wait fro the trade to happen and...
Pennystockformula - November 23, 2013

TPIV - NEWS

TapImmune Inc. (: TPIV) announced earlier this week theyhave begun a collaborative research and development agreement with Aeras, anon...
BigVanilla - November 8, 2011
View more Bullboard ››

TAG Oil Ltd.

TAG Oil Ltd.

TAG Oil Ltd. is an international oil and gas exploration company with a focus on operations and opportunities in the Middle ...
View More »